Alethia Young here one of the analysts on Deutsche Bank's biotechnology team. I am very happy to have with me Celldex Therapeutics and to my left I have Anthony Marucci, Founder, President and CEO; ...

Among the main indications for its lead clinical asset barzolvolimab, Celldex Therapeutics has been pursuing chronic spontaneous urticaria (CSU), along with prurigo nodularis (PN). This week the ...

HAMPTON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the second quarter ended June 30, 2025 and provided a corporate update.

Celldex Therapeutics has launched a Phase 2 study of its monoclonal antibody barzolvolimab for treating moderate to severe atopic dermatitis (AD), a common chronic skin condition affecting up to 20% ...

HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished ...